Register      Login

VOLUME 1 , ISSUE 1 ( January-March, 2022 ) > List of Articles


Let's Talk about Dex: When do the Benefits of Dexamethasone for Prevention of Bronchopulmonary Dysplasia Outweigh the Risks?

Thuy Nguyen, Brian K Jordan

Keywords : Bronchopulmonary dysplasia, Corticosteroids, Dexamethasone, Prematurity

Citation Information : Nguyen T, Jordan BK. Let's Talk about Dex: When do the Benefits of Dexamethasone for Prevention of Bronchopulmonary Dysplasia Outweigh the Risks?. 2022; 1 (1):91-96.

DOI: 10.5005/jp-journals-11002-0009

License: CC BY-NC 4.0

Published Online: 31-03-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Bronchopulmonary dysplasia (BPD) is the most common complication of extreme prematurity and carries increased respiratory morbidity into childhood and adulthood. Systemic administration of dexamethasone during the preterm period has been shown to decrease the incidence of BPD in this population. However, enthusiasm about its use has been tempered by early evidence that suggested potential adverse neurodevelopmental outcomes. More recent studies suggest that the timing, dosing, and duration of therapy may have a significant impact on the safety and efficacy of dexamethasone administration and that side effects and harms may be minimized if its use is appropriately targeted. Focusing on studies published since the 2010s American Academy of Pediatrics (AAP) statement on dexamethasone, this review seeks to examine the evidence from recent clinical trials to present the current state of knowledge regarding the systemic dexamethasone administration to prevent BPD in extremely premature infants and how dose, duration, and timing might impact its safety and efficacy in this vulnerable population.

  1. Narang I, Bush A. Early origins of chronic obstructive pulmonary disease. Semin Fetal Neonatal Med 2012;17(2):112–118. DOI: 10.1016/j.siny.2012.01.002.
  2. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. Lancet Respir Med 2013;1(9):728–742. DOI: 10.1016/S2213-2600(13)70118-8.
  3. Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373(2):111–122. DOI: 10.1056/NEJMoa1411532.
  4. Jordan BK, McEvoy CT. Trajectories of lung function in infants and children: setting a course for lifelong lung health. Pediatrics 2020;146(4):e20200417. DOI: 10.1542/peds.2020-0417.
  5. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354(20):2112–2121. DOI: 10.1056/NEJMoa054065.
  6. Darlow BA, Graham PJ, Rojas-Reyes MX. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. Cochrane Database Syst Rev 2016;(8):CD000501. DOI: 10.1002/14651858.CD000501.pub4.
  7. Doyle LW, Cheong JL, Ehrenkranz RA, et al. Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017;10:CD001145. DOI: 10.1002/14651858.CD001145.pub4.
  8. Olaloko O, Mohammed R, Ojha U. Evaluating the use of corticosteroids in preventing and treating bronchopulmonary dysplasia in preterm neonates. Int J Gen Med 2018;11:265–274. DOI: 10.2147/IJGM.S158184.
  9. Yoder MC, Chua R, Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1991;143(5 Pt 1):1044–1048. DOI: 10.1164/ajrccm/143.5_Pt_1.1044.
  10. Durand M, Mendoza ME, Tantivit P, et al. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 2002;109(2):262–268. DOI: 10.1542/peds.109.2.262.
  11. McEvoy C, Bowling S, Williamson K, et al. Functional residual capacity and passive compliance measurements after antenatal steroid therapy in preterm infants. Pediatr Pulmonol 2001;31(6):425–430. DOI: 10.1002/ppul.1070.
  12. Doyle LW, Ehrenkranz RA, Halliday HL. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2014;(5):CD001146. DOI: 10.1002/14651858.CD001146.pub4.
  13. Malaeb SN, Stonestreet BS. Steroids and injury to the developing brain: net harm or net benefit? Clin Perinatol 2014;41(1):191–208. DOI: 10.1016/j.clp.2013.09.006.
  14. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998;101(5):e7. DOI: 10.1542/peds.101.5.e7.
  15. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005;115(3):655–661. DOI: 10.1542/peds.2004-1238.
  16. Watterberg KL, American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement–postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126(4):800–808. DOI: 10.1542/peds.2010-1534.
  17. Yoder BA, Harrison M, Clark RH. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009;124(2):673–679. DOI: 10.1542/peds.2008-2793.
  18. Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006;117(1):75–83. DOI: 10.1542/peds.2004-2843.
  19. Doyle LW, Davis PG, Morley CJ, et al. Outcome at 2 years of age of infants from the dart study: a multicenter, international, randomized, controlled trial of low-dose dexamethasonef. Pediatrics 2007;119(4):716–721. DOI: 10.1542/peds.2006-2806.
  20. Cuna A, Govindarajan S, Oschman A, et al. A comparison of 7-day versus 10-day course of low-dose dexamethasone for chronically ventilated preterm infants. J Perinatol 2017;37(3):301–305. DOI: 10.1038/jp.2016.215.
  21. Cuna A, Lewis T, Dai H, et al. Timing of postnatal corticosteroid treatment for bronchopulmonary dysplasia and its effect on outcomes. Pediatr Pulmonol 2019;54(2):165–170. DOI: 10.1002/ppul. 24202.
  22. Marr BL, Mettelman BB, Bode MM, et al. Randomized trial of 42-day compared with 9-day courses of dexamethasone for the treatment of evolving bronchopulmonary dysplasia in extremely preterm infants. J Pediatr 2019;211:20–26.e1. DOI: 10.1016/j.jpeds.2019.04.047.
  23. Onland W, De Jaegere AP, Offringa M, et al. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017;1:CD010941. DOI: 10.1002/14651858.CD010941.pub2.
  24. Harmon HM, Jensen EA, Tan S, et al. Timing of postnatal steroids for bronchopulmonary dysplasia: association with pulmonary and neurodevelopmental outcomes. J Perinatol 2020;40(4):616–627. DOI: 10.1038/s41372-020-0594-4.
  25. Ramaswamy VV, Bandyopadhyay T, Nanda D, et al. Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates: a systematic review and network meta-analysis. JAMA Pediatr 2021;175(6):e206826. DOI: 10.1001/jamapediatrics.2020.6826.
  26. Nath S, Reynolds AM, Lakshminrusimha S, et al. Retrospective analysis of short-term respiratory outcomes of three different steroids used in clinical practice in intubated preterm infants. Am J Perinatol 2020;37(14):1425–1431. DOI: 10.1055/s-0039-1694004.
  27. Watterberg KL. A randomized controlled trial of the effect of hydrocortisone on survival without bronchopulmonary dysplasia and on neurodevelopmental impairment at 2 years in intubated infants born <30 weeks gestation age (GA). Pediatric Academic Societies Meeting; 2021.
  28. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001144. DOI: 10.1002/14651858.CD001144.
  29. Karna P, Muttineni J, Angell L, et al. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr 2005;5(1):18. DOI: 10.1186/1471-2431-5-18.
  30. Smolkin T, Steinberg M, Sujov P, et al. Late postnatal systemic steroids predispose to retinopathy of prematurity in very-low-birth-weight infants: a comparative study. Acta Paediatr 2008;97(3):322–326. DOI: 10.1111/j.1651-2227.2008.00629.x.
  31. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001;1:1. DOI: 10.1186/1471-2431-1-1.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.